The Effect of TALENs-mediated Downregulation Expression of Nanog on Malignant Behavior of Cervical Cancer HeLa Cells

YU Ai-qing, LI Cheng-lin, Yang-Yi. et al

Abstract

To study the effect of downregulation expression of Nanog on malignant behavior of cervical cancer HeLa cells. Methods Gene editing tool TALENs was employed to induce downregulation expression of Nanog, and Nanog mutation was evaluated by sequencing. RT-PCR and Western blot was used to detect the mRNA and protein expression level, respectively. Colony-formation assay, Transwell invasion assay, and chemotherapy sensibility assay was carried out to assess the capacity of colony-formation, invasion, and chemoresistance, respectively. Results TALENs successfully induced Nanog mutation and downregulated Nanog expression. Nanog mRNA and protein expression of Nanog-mutated monoclonal HeLa cells downregulated 3 times compared to thoses of wild-type HeLa cells (P<0.05). Additionally, significant weakened abilities of colony-formation, invasion, and chemoresistance in monoclonal HeLa cells were observed when compared to those of wild-type HeLa cells (P<0.05). Conclusion Nanog mutation attenuates the malignant behavior of HeLa cells. Importantly, downregulation or silencing of Nanog is promising to be a novel strategy for the treatment of cervical carcinoma.

 

Keywords: TALENs, Nanog, HeLa cells, Cervical cancer 


Full Text:

PDF


References


Missaoui N, Hmissa S, Trabelsi A, et al. Promoter hypermethylation of CDH13, DAPK1 and TWIST1 genes in precancerous and cancerous lesions of the uterine cervix. Pathol Res Pract,2011;207(1):37-42.

Wang JT, Ding L. Jiang SW, et al. Folate deficiency and aberrant expression of DNA methyltransferase 1 were associated with cervical cancerization. Curr Pharm, 2014; 20(11):1639-1646.

Punt S. Thijssen VL, Vrolijk J, et al. Galectin-1, -3 and -9 expression and clinical significance in squamous cervical cancer. PLoS One.2015; 10(6) :e0129119. doi: 10. 1371/journal, pone. 0129119.

Attaleb M. El-hamadani W, Khyatti M. et al. Status of pi6 ( INKla ) and E-cadherin gene promoter methylation in Moroccan patients with cervical carcinoma. Oncol Res,2009; 18 (4):185-192.

Zhang Y, Chen FQ, Sun YH, et al. Effects of DNMT1 silencing on malignant phenotype and methylated gene expression in cervical cancer cells. J Exp Clin Cancer Res, 2011 ;30:98. doi: 10. 1186/1756-9966-30-98.

Go MJ, Takenaka С, Ohgushi H. Forced expression of Sox2 or Nanog in human bone marrow derived mesenchymal stem cells maintains their expansion and differentiation capabilities. Exp Cell Res,2008;314(5): 1147-1154.

Pan G, Pei D. The stem cell pluripotency factor NANOG activates transcription with two unusually potent subdomains at its С terminus. J Biol Chem,2005;280(2): 1401-1407.

Wu J. Tzanakakis ES. Distinct allelic patterns of Nanog expression impart embryonic stem cell population heterogeneity. PLoS Comput Biol, 2013; 9 ( 7 ); el003140. doi: 10. 1371/journal, pcbi. 1003140.

Luo Y, Lim CL. Nichols J, et al. Cell signalling regulates dynamics of Nanog distribution in embryonic stem cell populations. J R Soc Interface, 2012 Oct 10. Epub ahead of print].

Bourguignon LY, Earle C, Wong G, et at. Stem cell marker ( Nanog ) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CDl4-activated head and neck squamous cell carcinoma cells. Oncogene,2012; 31(2):149-160.

Sun C, Sun L, Jiang K, et al. NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway. Int J Biochem Cell Biol, 2013; 4 5(6): 1099-1108.

Santaliz-Ruiz LE, Xie X. Old M. et al. Emerging role of nanog in tumorigenesis and cancer stem cells. Int J Cancer, 2014; 135(12);2741-2748.

Ji W. Jiang Z. Effect of shRNA-mediated inhibition of Nanog gene expression on the behavior of human gastric cancer cells. Oncol Lett ,2013;6(2);367-374.

Katsuyama T. Akmammedov А, Seimiya M. et al. An efficient strategy for TALEN-mediated genome engineering in Drosophila. Nucleic Acids Res, 2013; 41 (17) ; el63. doi: 10. 1093/nar/gkt638.

Li T, Huang S, Zhao X, et al. Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes. Nucleic Acids Res, 2011; 39 ( 14 ) ; 6315-6325.

Lu Y, Zhu H. Shan H, et al. Knockdown of Oct4 and Nanog expression inhibits the sternness of pancreatic cancer cells. Cancer Lett,2013;340( 1): 113-123.

Bar-Nur O, Brum baugh J, Verheul C, et al. Small molecules facilitate rapid and synchronous iPSC generation. Nat Methods,2014; 11( 11) ; 1170-1176.

Wang D. Lu P. Zhang H, et al. Oct-4 and nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget,2014;5(21): 10803-10815.

Jeter CR, Liu B, Liu X. et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene,2011;30(36);3833-3845.

Huang CE, Yu CC,Hu FW, et al. Enhanced chemosensitivity by targeting Nanog in head and neck squamous cell carcinomas. Int J Mol Sci,2014; 15(9): 14935-14948.

Meng HM, Zheng P, Wang XY, et al. Overexpression of Nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther,2010;9(4) ;295-302.

Chiou SH, Wang ML. Chou YT, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial- mesenchymal transdifferentiation. Cancer Res, 2010; 70 ( 24 ): 10433-10444.

Lee M, Nam EJ. Kim SW. et al. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma. Int J Gynecol Cancer,2012;22(9); 1489-1496.


Refbacks

  • There are currently no refbacks.